10-Q: Precigen Reports Q1 2025 Results, Faces Going Concern Uncertainty Despite PRGN-2012 Priority Review

Precigen's Q1 2025 results reveal a net loss of $54.15 million and raise substantial doubt about its ability to continue as a going concern, despite FDA priority review for PRGN-2012.

Summary

• Precigen reported a net loss of $54.15 million for the three months ended March 31, 2025, compared to a net loss of $23.74 million for the same period in 2024.
• The company's cash and investments totaled $80.99 million as of March 31, 2025.
• Management expresses substantial doubt about the company's ability to continue as a going concern, citing operating losses and limited committed funding.
• Revenue increased to $1.34 million from $1.07 million year-over-year, driven by growth in product and service revenues at Exemplar.
• Research and development expenses decreased to $10.48 million from $14.25 million year-over-year, primarily due to the shutdown of ActoBio operations and strategic prioritization efforts.
• Selling, general, and administrative expenses increased to $12.36 million from $10.15 million year-over-year, mainly due to PRGN-2012 commercial readiness activities.
• The FDA granted priority review to Precigen's Biologics License Application (BLA) for PRGN-2012, with a target action date of August 27, 2025.
• The company realigned its operating segments into one to streamline operations and focus on core business activities.
• A charge related to employee severance and termination benefits of $1,639 was recorded during 2024 as part of the strategic prioritization.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there is some positive news regarding revenue growth and the FDA's priority review of PRGN-2012, the significant net loss and concerns about the company's ability to continue as a going concern weigh heavily on the overall sentiment.

Positives

• Revenue increased by 25.9% to $1.34 million, driven by Exemplar's performance.
• Research and development expenses decreased by 26.5% to $10.48 million due to strategic prioritization and the shutdown of ActoBio.
• The FDA granted priority review for PRGN-2012, setting a PDUFA target action date for August 27, 2025.

Negatives

• Precigen's Q1 2025 net loss widened to $54.15 million from $23.74 million in Q1 2024.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company recorded a $32.5 million increase in the fair value of warrant liabilities.

Risks

• The company's ability to continue as a going concern is uncertain due to operating losses and limited committed funding.
• The company's future success depends on obtaining regulatory approval for its product candidates, particularly PRGN-2012.
• The company may need to raise additional capital, which could dilute existing shareholders or impose restrictive covenants.
• The company faces risks associated with research and development, competition, and intellectual property protection.
• The company is involved in ongoing legal proceedings, which could result in adverse judgments or settlements.

Future Outlook

The company is focused on the potential commercialization of PRGN-2012 and is accelerating commercial readiness efforts for a potential launch in 2025. The company plans to minimize UltraCAR-T spending and focus on strategic partnerships to further advance UltraCAR-T programs. The company plans to enroll patients in the PRGN-2009 clinical trials only at NCI under a CRADA.

Management Comments

• Management expresses substantial doubt about the company's ability to continue as a going concern.
• Management believes that its existing cash, cash equivalents and short-term investments, combined with anticipated potential revenue from the commercialization of PRGN-2012, which is outside of our direct control, will enable us to continue our operations for at least one year from the date of this filing.

Industry Context

Precigen is operating in the competitive biopharmaceutical industry, focusing on gene and cell therapies. The company's strategic prioritization and focus on PRGN-2012 reflect a trend among biotech companies to streamline operations and concentrate resources on lead programs with near-term commercial potential. The company's reliance on potential revenue from PRGN-2012 highlights the high-risk, high-reward nature of the industry, where regulatory approvals can significantly impact a company's financial outlook.

Comparison to Industry Standards

• It is difficult to compare Precigen's results directly to industry standards without knowing the specific peer group.
• However, the company's increased net loss and concerns about its ability to continue as a going concern are concerning compared to industry benchmarks.
• Many companies in the biopharmaceutical industry are focusing on streamlining operations and prioritizing key programs, which is similar to Precigen's strategy.
• The company's reliance on potential revenue from PRGN-2012 is a common risk factor in the industry, as regulatory approvals are uncertain and can significantly impact financial performance.
• Companies like CRISPR Therapeutics, bluebird bio, and Beam Therapeutics are also focused on gene and cell therapies, but their financial situations and clinical progress may vary significantly.

Legal Proceedings

• The company is involved in litigation or legal matters, including governmental investigations.
• In December 2020, a derivative shareholder action, captioned Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al , was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc.
• On September 24, 2021, an individual shareholder filed a lawsuit in the Circuit Court for Henrico County styled Kent v. Precigen , Inc., Case CL21-6349.

Stakeholder Impact

• Shareholders face potential dilution if the company raises additional capital.
• Employees may be affected by the company's strategic prioritization and cost-cutting measures.
• Customers of Exemplar may experience changes in product and service offerings.
• Suppliers and creditors may be impacted by the company's financial challenges.

Next Steps

• The company will focus on obtaining regulatory approval for PRGN-2012.
• The company will conduct a confirmatory clinical trial for PRGN-2012.
• The company will continue manufacturing commercial product for PRGN-2012.
• The company will continue acceleration of commercial readiness efforts for a potential launch.
• The company will focus on strategic partnership opportunities to advance PRGN-3006 UltraCAR-T program in AML.

Key Dates

Keywords

PRGN-2012, AdenoVerse, UltraCAR-T, Exemplar, RRP, BLA, FDA, Going Concern, Financial Results, Precigen